Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Comment by narmacon Feb 28, 2021 1:48pm
202 Views
Post# 32681827

RE:Eldon Smith?

RE:Eldon Smith?
,,probably when either the Hepalink and or ORi rep took a seat on the BoD.,,,,,the BoD I think is mostly accounting types which is fascinating that this company has failed miserably in the business sense. Not sure where the problem is within...Moon,,seems to be a stuffed shirt!...the science seems to have a footing,,based on peer reviewed articles,,,but their is no proactive business being developed,,,,,,seems a lot of stay at home and blame covid or find a hedge fund to blame for the share price.,,,,when it really boils down to the teams inability to sell the science. All the while market is starving to find the next cutting egde company to invest in. Its just incomprehensible.
<< Previous
Bullboard Posts
Next >>